Skip to main content

Table 3 Subgroup analyses of the relationships between CD133 ovexpression and overall survival or progression-free-survival

From: Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis

Comparison variables

Overall survival

Progression-free survival

Number of studies, Heterogeneity (I2 statistics; %)

HR 95 % CI, P value

Interaction, P value

Number of studies, Heterogeneity (I2 statistics; %)

HR 95 % CI, P value

Interaction, P value

Total

11 (77.8)

1.69 (1.16–2.47), 0.006

NA

8 (68.2)

1.64 (1.12–2.39), 0.010

NA

Origin country

      

Europe

8 (81.0)

1.63 (1.03–2.61), 0.039

0.030

6 (76.5)

1.74 (1.06–2.83), 0.027

0.579

Asian

3 (42.5)

1.85 (1.02–3.35), 0.044

 

2 (0.0)

1.37 (0.86–2.18), 0.188

 

Sample size

      

>50

4 (77.4)

1.45 (0.91–2.31), 0.116

0.000

3 (0.0)

1.37 (1.01–1.73), 0.009

0.092

≤50

7 (67.6)

1.94 (1.07–3.54), 0.030

 

5 (77.0)

1.99 (0.94–4.22), 0.073

 

Follow up period

      

1,>media 12months

4 (74.1)

2.48 (1.13–5.45), 0.024

0.000

3 (86.7)

2.64 (0.98–7.11), 0.054

0.060

2,≤media 12months

3 (43.0)

0.90 (0.54–1.49), 0.678

 

3 (0.0)

1.12 (0.79–1.57), 0.530

 

3,No Referreed

4 (0)

2.11 (1.52–2.93), 0.000

 

2 (0.0)

1.64 (1.19–2.27), 0.003

Median/mean age y

      

Referred

6 (0.0)

1.85 (1.45–2.37), 0.000

0.000

3 (0.0)

1.59 (1.24–2.04), 0.000

0.713

No Referred

5 (79.8)

1.57 (0.70–3.55), 0.274

 

5 (80.8)

1.79 (0.81–3.97), 0.153

 

Test method

      

IHC

5 (64.8)

2.16 (1.25–3.73), 0.006

0.000

4 (80.9)

2.25 (1.11–4.58), 0.025

0.122

Others

6 (71.2)

1.37 (0.85–2.22), 0.202

 

4 (20.4)

1.31 (0.93–1.84), 0.122

 

Cut‑off level

      

1:median

4 (61.4)

1.09 (0.66–1.79) 0.748

0.000

3 (0.0)

1.12 (0.79–1.57), 0.530

0.024

2:others

7 (51.3)

2.17 (1.44–3.27), 0.000

 

5 (74.5)

2.07 (1.25–3.43), 0.005

 

WHO grade

      

IV

8 (76.3)

1.73 (1.20–2.50), 0.004

0.915

5 (0.00)

1.46 (1.19–1.80), 0.000

0.143

II–III

3 (87.0)

2.38 (0.30–18.82), 0.411

 

3 (88.1)

2.17 (0.42–11.28), 0.355